Affiliation:
1. State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
2. Tianjin Modern Innovation Chinese Medicine Technology Co., Ltd., Tianjin 300380, China
Abstract
Background:
Xuanfei Baidu granules (XFBD granules) are based on the prescription of Xuanfei Baidu,
which showed promise as a first-line treatment against Corona Virus Disease 2019 (COVID-19) in Wuhan, Hubei.
On March 2, 2021, XFBD granules were marketed as a novel drug for epidemic diseases. However, there is little
information about the pharmacokinetics and tissue distribution of the main constituents in XFBD granules.
Methods:
A sensitive analytical method was developed for detecting the marker components of XFBD granules by
ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOFMS/
MS), and for studying its pharmacokinetics and tissue distribution by UPLC-QDa.
Results:
Following an oral administration of a single granule in experimental rats at a dose of 14 g/kg for pharmacokinetic
and tissue distribution studies, 42 compounds and nine analytes were identified in XFBD granules. Nine
compounds were detected in the lungs and the liver of the rats. Six compounds were detected in the kidneys. Five
compounds were detected in the spleen and three were detected in the heart. As it went undetected in the brain,
XFBD granules are considered unable to cross the blood-brain barrier.
Conclusion:
A sensitive UPLC-Q-TOF-MS/MS method was established and validated for the quantification of nine
components in rat plasma and tissue samples. This method was successfully applied to study the pharmacokinetics
and tissue distribution profiles of XFBD granules after their oral administration.
Funder
National Key Research and Development Project of China
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Pharmacology
Reference26 articles.
1. Ren J.L.; Zhang A.H.; Wang X.J.; Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res 2020,155
2. Guo D.A.; Liu C.X.; Rudolf Bauer: China anti-COVID-19 success is closely related with the role TCM played. Chin Herb Med 2020,12(4),347-348
3. Wang Y.; Li X.; Zhang J.H.; Xue R.; Qian J.Y.; Zhang X.H.; Zhang H.; Liu Q.Q.; Fan X.H.; Cheng Y.Y.; Zhang B.L.; Mechanism of Xuanfei Baidu Tang in treatment of COVID-19 based on network pharmacology. Zhongguo Zhongyao Zazhi 2020,45(10),2249-2256
4. Yue X.; Lu L.; Liu H.; Xue H.; Pharmacokinetics, bioavailability and metabolism of cligosiban, an antagonist of oxytocin receptor, in rat by liquid chromatography hyphenated with electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal 2019,164,725-733
5. Niu W.H.; Wu F.; Cao W.Y.; Wu Z.G.; Chao Y.C.; Liang C.; Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin- 6. Biosci Rep 2021,41(1),41